OXFORD, England, September 30, 2013 /PRNewswire/ —

PharmaVentures is pleased to announce that it has acted as exclusive M&A advisor to NanoSight in the successful sale of the company to Malvern Instruments, a Spectris plc company. Malvern completed the acquisition on 30^th September 2013.

NanoSight’s business is based upon its unique Nanoparticle Tracking Analysis (NTA) instrumentation and software technology and their application across life science and non-life science research. The acquisition follows exceptional year-on-year revenue growth for NanoSight with the company being named as one of 100 fastest growing tech companies in Britain in 2013.

This successful sale also builds on PharmaVentures reputation and success in the M&A field.

Fintan Walton, CEO, PharmaVentures Ltd said: “PharmaVentures is delighted to have worked with NanoSight to find the ideal acquirer who can take the company and its unique technology to next level.”

Adrian Dawkes, VP, who led the transaction team at PharmaVentures added: “This is a fantastic outcome for NanoSight as it will expand their presence in existing markets and give access to previously untapped regions via Malvern’s established presence and respected brand.”

Over the past 21 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. Their unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support businesses in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success in transactions.

Find out more http://www.pharmaventures.com.

Our services include:

• M&A (divestments, mergers, acquisitions and strategic transactions)
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
• Licensing (in and out licensing)
• Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now in its 22nd year, PharmaVentures is based in Oxford, UK, with offices in London and San Francisco.

For further information, contact:
Dr Fintan Walton
CEO
PharmaVentures Ltd
+44(0)1865-332727
enquiries@pharmaventures.com

SOURCE PharmaVentures